A Spanish clinic with extensive experience in the field of mesenchymal stem cells is looking for public or private organizations that have experts in cell culture in bioreactors and specialists in microvesicle characterization to develop a new cancer therapy based on the secretion of human mesenchymal stem cells from the human cervix.
While unprecedented advances have been made in stem cell research over the past decade, the challenge still remains to find a cost-effective therapy for the comprehensive treatment of aggressive cancers.
The project proposed by the clinic is aimed at developing a new cancer therapy based on the secretion of mesenchymal stem cells of the human cervix. The specific goal is to complete the preclinical studies required to conduct clinical trials using conditioned medium (MC) and microvesicles derived from mesenchymal stem cells of the cervix (hUCESC) as an innovative therapeutic approach for breast, ovarian and pancreatic cancers.
Foreign organizations are planned to be involved in solving the following specific tasks:
- Increased bioreactor yield of hUCESCs and MC production.
- Optimization of the isolation and functional characteristics of the microvesicles present in MC, which should lead to the maximum antitumor effect. In addition, it is necessary to carry out the phenotypic and molecular characterization of different populations of microvesicles obtained from the secretome, corresponding to different experimental conditions of problem 1.
The project will be submitted to the competition “HORIZON-EIC-2021-PATHFINDERCHALLENGES-01-03: New technologies in cell and gene therapy” (maximum budget 4 million euros).
The project is designed for 36 weeks.
The deadline for filing expressions of interest is September 27, 2021.
Application deadline October 27, 2021.